{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T08:40:23Z","timestamp":1773218423160,"version":"3.50.1"},"reference-count":38,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.2016.0445","type":"journal-article","created":{"date-parts":[[2018,5,2]],"date-time":"2018-05-02T09:27:14Z","timestamp":1525253234000},"source":"Crossref","is-referenced-by-count":12,"title":["Ezetimibe-Statin Combination Therapy: Efficacy and Safety as Compared With Statin Monotherapy"],"prefix":"10.3238","author":[{"given":"Barbara","family":"Nu\u00dfbaumer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Glechner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Kaminski-Hartenthaler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Mahlknecht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerald","family":"Gartlehner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"11437","published-online":{"date-parts":[[2016,7,1]]},"reference":[{"key":"10.3238\/arztebl.2016.0445_ref1","unstructured":"World Health Organization (WHO): H\u00e4ufigste Todesursachen in Europa: Faktenblatt 2013. www.euro.who.int\/__data\/assets\/pdf_file\/0020\/185312\/Leading-causes-of-death-in-Europe-Fact-Sheet-Ger.pdf?ua=1 (last accessed on 9 September 2015)."},{"key":"10.3238\/arztebl.2016.0445_ref2","doi-asserted-by":"crossref","unstructured":"Reddigan JI, Ardern CI, Riddell MC, Kuk JL: Relation of physical activity to cardiovascular disease mortality and the influence of cardiometabolic risk factors. Am J Cardiol 2011; 108: 1426\u201331","DOI":"10.1016\/j.amjcard.2011.07.005"},{"key":"10.3238\/arztebl.2016.0445_ref3","doi-asserted-by":"crossref","unstructured":"Dehghan M, Mente A, Teo KK, et al.: Relationship between healthy diet and risk of cardiovascular disease among patients on drug therapies for secondary prevention: a prospective cohort study of 31 546 high-risk individuals from 40 countries. Circulation 2012; 126: 2705\u201312","DOI":"10.1161\/CIRCULATIONAHA.112.103234"},{"key":"10.3238\/arztebl.2016.0445_ref4","doi-asserted-by":"crossref","unstructured":"Hurt RD, Weston SA, Ebbert JO, et al.: Myocardial infarction and sudden cardiac death in Olmsted County, Minnesota, before and after smoke-free workplace laws. Arch Intern Med 2012; 172: 1635\u201341","DOI":"10.1001\/2013.jamainternmed.46"},{"key":"10.3238\/arztebl.2016.0445_ref5","doi-asserted-by":"crossref","unstructured":"EUROASPIRE II Study Group: Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries. Eur Heart J 2001; 22: 554\u201372","DOI":"10.1053\/euhj.2001.2610"},{"key":"10.3238\/arztebl.2016.0445_ref6","doi-asserted-by":"crossref","unstructured":"British Cardiac Society, British Hypertension Society, Diabetes UK, et al.: JBS 2: Joint British Societies\u2019 guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005; 91 (Suppl 5): v1\u201352","DOI":"10.1136\/hrt.2005.079988"},{"key":"10.3238\/arztebl.2016.0445_ref7","doi-asserted-by":"crossref","unstructured":"Studer M, Briel M, Leimenstoll B, Glass TR, Bucher HC: Effect of different antilipidemic agents and diets on mortality: a systematic review. Arch Intern Med 2005; 165: 725\u201330","DOI":"10.1001\/archinte.165.7.725"},{"key":"10.3238\/arztebl.2016.0445_ref8","doi-asserted-by":"crossref","unstructured":"Shepherd J, Cobbe SM, Ford I, et al.: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301\u20137","DOI":"10.1056\/NEJM199511163332001"},{"key":"10.3238\/arztebl.2016.0445_ref9","doi-asserted-by":"crossref","unstructured":"Taylor F, Huffman MD, Macedo AF, et al.: Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2013; 1: CD004816","DOI":"10.1002\/14651858.CD004816.pub5"},{"key":"10.3238\/arztebl.2016.0445_ref10","unstructured":"Fachinformation Ezetrol \u00ae 10mg Tabletten, Stand 2\/2016. www.msd.de\/fileadmin\/files\/fachinformationen\/ezetrol.pdf (last accessed on 9 September 2015)."},{"key":"10.3238\/arztebl.2016.0445_ref11","unstructured":"Angelopoulos J, Krassakopoulos N, Nathanson R, Boukas S, Sampalis JS: Co-administration of ezetimibe and a statin in management of dyslipidemias: a meta-analysis of clinical trials. Arch Med Sci 2009; 5: 347\u201363."},{"key":"10.3238\/arztebl.2016.0445_ref12","doi-asserted-by":"crossref","unstructured":"Mikhailidis DP, Sibbring GC, Ballantyne CM, Davies GM, Catapano AL: Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy. Curr Med Res Opin 2007; 23: 2009\u201326","DOI":"10.1185\/030079907X210507"},{"key":"10.3238\/arztebl.2016.0445_ref13","doi-asserted-by":"crossref","unstructured":"Charland SL, Malone DC: Prediction of cardiovascular event risk reduction from lipid changes associated with high potency dyslipidemia therapy. Curr Med Res Opin 2010; 26: 365\u201375","DOI":"10.1185\/03007990903484802"},{"key":"10.3238\/arztebl.2016.0445_ref14","doi-asserted-by":"crossref","unstructured":"Sharma M, Ansari MT, Abou-Setta AM, et al.: Systematic review: comparative effectiveness and harms of combination therapy and monotherapy for dyslipidemia. Ann Intern Med 2009; 151: 622\u201330","DOI":"10.7326\/0003-4819-151-9-200911030-00144"},{"key":"10.3238\/arztebl.2016.0445_ref15","doi-asserted-by":"crossref","unstructured":"Ye Y, Zhao X, Zhai G, et al.: Effect of high-dose statin versus low-dose statin plus ezetimibe on endothelial function: a meta-analysis of randomized trials. J Cardiovasc Pharmacol Ther 2012; 17: 357\u201365","DOI":"10.1177\/1074248412449384"},{"key":"10.3238\/arztebl.2016.0445_ref16","doi-asserted-by":"crossref","unstructured":"Ara R, Tumur I, Pandor A, et al.: Ezetimibe for the treatment of hypercholesterolaemia: a systematic review and economic evaluation. Health Technol Assess. 2008; 12: iii, xi-xiii, 1\u2013212","DOI":"10.3310\/hta12210"},{"key":"10.3238\/arztebl.2016.0445_ref17","unstructured":"Institut f\u00fcr Qualit\u00e4t und Wirtschaftlichkeit im Gesundheitswesen (IQWIG): Ezetimib bei Hypercholesterin\u00e4mie. Abschlussbericht, Stand: 7\/2011. www.iqwig.de\/download\/A10\u201302_Abschlussbericht_Ezetimib_bei_Hypercholesterinaemie.pdf (last accessed on 9 September 2015)."},{"key":"10.3238\/arztebl.2016.0445_ref18","unstructured":"Nussbaumer B, Mahlknecht P, Glechner A, et al.: Efficacy and risk of harms of ezetimibe in hyperlipidemic patients with or without atherosclerosis and\/or diabetes mellitus. PROSPERO 2014: CRD42014013687. (last accessed on 2 September 2015)."},{"key":"10.3238\/arztebl.2016.0445_ref19","unstructured":"Higgins JPT, Green S: Cochrane handbook for systematic reviews of interventions version 5.1.0 (updated March 2011). The Cochrane Collaboration 2011. handbook.cochrane.org (last accessed on 9 September 2015)."},{"key":"10.3238\/arztebl.2016.0445_ref20","doi-asserted-by":"crossref","unstructured":"Arimura T, Miura S, Ike A, et al.: Comparison of the efficacy and safety of statin and statin\/ezetimibe therapy after coronary stent implantation in patients with stable angina. J Cardiol 2012; 60: 111\u20138","DOI":"10.1016\/j.jjcc.2012.03.002"},{"key":"10.3238\/arztebl.2016.0445_ref21","doi-asserted-by":"crossref","unstructured":"Dagli N, Yavuzkir M, Karaca I: The effects of high dose pravastatin and low dose pravastatin and ezetimibe combination therapy on lipid, glucose metabolism and inflammation. Inflammation 2007; 30: 230\u20135","DOI":"10.1007\/s10753-007-9041-3"},{"key":"10.3238\/arztebl.2016.0445_ref22","doi-asserted-by":"crossref","unstructured":"Feldman T, Koren M, Insull W Jr., et al.: Treatment of high-risk patients with ezetimibe plus simvastatin co-administration versus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III low-density lipoprotein cholesterol goals. Am J Cardiol 2004; 93: 1481\u20136","DOI":"10.1016\/j.amjcard.2004.02.059"},{"key":"10.3238\/arztebl.2016.0445_ref23","doi-asserted-by":"crossref","unstructured":"Gaudiani LM, Lewin A, Meneghini L, et al.: Efficacy and safety of ezetimibe co-administered with simvastatin in thiazolidinedione-treated type 2 diabetic patients. Diabetes Obes Metab 2005; 7: 88\u201397","DOI":"10.1111\/j.1463-1326.2004.00420.x"},{"key":"10.3238\/arztebl.2016.0445_ref24","doi-asserted-by":"crossref","unstructured":"Meaney A, Ceballos G, Asbun J, et al.: The VYtorin on carotid intima-media thickness and overall arterial rigidity (VYCTOR) study. J Clin Pharmacol 2009; 49: 838\u201347","DOI":"10.1177\/0091270009337011"},{"key":"10.3238\/arztebl.2016.0445_ref25","doi-asserted-by":"crossref","unstructured":"Nakamura T, Hirano M, Kitta Y, et al.: A comparison of the efficacy of combined ezetimibe and statin therapy with doubling of statin dose in patients with remnant lipoproteinemia on previous statin therapy. J Cardiol 2012; 60: 12\u201317 CrossRef","DOI":"10.1016\/j.jjcc.2012.02.005"},{"key":"10.3238\/arztebl.2016.0445_ref26","doi-asserted-by":"crossref","unstructured":"West AM, Anderson JD, Meyer CH, et al.: The effect of ezetimibe on peripheral arterial atherosclerosis depends upon statin use at baseline. Atheroscler 2011; 218: 156\u201362","DOI":"10.1016\/j.atherosclerosis.2011.04.005"},{"key":"10.3238\/arztebl.2016.0445_ref27","doi-asserted-by":"crossref","unstructured":"Blazing M, Giugliano RP, Cannon CP, et al.: Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study population. Am Heart J 2014; 168: 205\u201312.e1","DOI":"10.1016\/j.ahj.2014.05.004"},{"key":"10.3238\/arztebl.2016.0445_ref28","doi-asserted-by":"crossref","unstructured":"Cannon CP, Blazing MA, Giugliano RP, et al.: Ezetimibe added to statin therapy after acute coronary syndromes. N Eng J Med 2015; 372: 2387\u201397","DOI":"10.1056\/NEJMoa1410489"},{"key":"10.3238\/arztebl.2016.0445_ref29","doi-asserted-by":"crossref","unstructured":"Masuda J, Tanigawa T, Yamada T, et al.: Effect of combination therapy of ezetimibe and rosuvastatin on regression of coronary atherosclerosis in patients with coronary artery disease. Int Heart J 2015; 56: 278\u201385","DOI":"10.1536\/ihj.14-311"},{"key":"10.3238\/arztebl.2016.0445_ref30","doi-asserted-by":"crossref","unstructured":"Falck-Ytter Y, Sch\u00fcnemann H, Guyatt G: AHRQ series commentary 1: rating the evidence in comparative effectiveness reviews. J Clin Epidemiol 2010; 63: 474\u20135","DOI":"10.1016\/j.jclinepi.2010.01.003"},{"key":"10.3238\/arztebl.2016.0445_ref31","unstructured":"Mantel N, Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 719\u2013748"},{"key":"10.3238\/arztebl.2016.0445_ref32","doi-asserted-by":"crossref","unstructured":"Higgins J, Thompson SG: Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 1539\u201358","DOI":"10.1002\/sim.1186"},{"key":"10.3238\/arztebl.2016.0445_ref33","unstructured":"Merck S, Dohme C. IMPROVE-IT: Examining outcomes in subjects with acute coronary syndrome: vytorin (ezetimibe\/simvastatin) vs simvastatin (P04103). (last accessed on 9 February 2016)."},{"key":"10.3238\/arztebl.2016.0445_ref34","doi-asserted-by":"crossref","unstructured":"National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143\u201321.","DOI":"10.1161\/circ.106.25.3143"},{"key":"10.3238\/arztebl.2016.0445_ref35","unstructured":"International Conference on Harmonisation (ICH): Guideline for good clinical practice E6(R1). Current step 4 version 1996. www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Efficacy\/E6\/E6_R1_Guideline.pdf (last accessed on 9 February 2016)."},{"key":"10.3238\/arztebl.2016.0445_ref36","doi-asserted-by":"crossref","unstructured":"Bass A, Hinderliter AL, Lee CR: The impact of ezetimibe on endothelial function and other markers of cardiovascular risk. Ann Pharmacother 2009; 43: 2021\u201330","DOI":"10.1345\/aph.1M302"},{"key":"10.3238\/arztebl.2016.0445_ref37","doi-asserted-by":"crossref","unstructured":"Slim H, Thompson PD: Ezetimibe-related myopathy: a systematic review. J Clin Lipidol 2008; 2: 328\u201334","DOI":"10.1016\/j.jacl.2008.08.430"},{"key":"10.3238\/arztebl.2016.0445_ref38","doi-asserted-by":"crossref","unstructured":"Pandor A, Ara RM, Tumur I, et al.: Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials. J Int Med 2009; 265: 568\u201380","DOI":"10.1111\/j.1365-2796.2008.02062.x"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2016.0445","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T13:39:29Z","timestamp":1638797969000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2016.0445"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,1]]},"references-count":38,"URL":"https:\/\/doi.org\/10.3238\/arztebl.2016.0445","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,1]]}}}